Literature DB >> 11807979

Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.

Sukvarsha Mehra1, Hans Messner, Mark Minden, R S K Chaganti.   

Abstract

Spectral karyotyping (SKY) and comparative genomic hybridization (CGH) have greatly enhanced the resolution of cytogenetic analysis, enabling the identification of novel regions of rearrangement and amplification in tumor cells. Here we report the analysis of 10 malignant non-Hodgkin lymphoma (NHL) cell lines derived at the Ontario Cancer Institute (OCI), Toronto, designated as OCI-Ly1, OCI-Ly2, OCI-Ly3, OCI-LY4, OCI-Ly7, OCI-Ly8, OCI-Ly12, OCI-Ly13.2, OCI-Ly17, and OCI-Ly18, by G-banding, SKY, and CGH, and we present their comprehensive cytogenetic profiles. In contrast to the 52 breakpoints identified by G-banding, SKY identified 87 breakpoints, which clustered at 1q21, 7p15, 8p11, 13q21, 13q32, 14q32, 17q11, and 18q21. G-banding identified 10 translocations, including the previously described recurring translocations, t(8;14)(q24;q32) and t(14;18)(q32;q21). In contrast, SKY identified 60 translocations, including five that were recurring, t(8;14)(q24;q32), t(14;18)(q32;q21), t(4;7)(p12;q22), t(11;18)(q22;q21), and t(3;18)(q21;p11). SKY also identified the source of all the marker chromosomes. In addition, 10 chromosomes that were classified as normal by G-banding were found by SKY to be rearranged. CGH identified seven sites of high-level DNA amplification, 1q31-32, 2p12-16, 8q24, 11q23-25, 13q21-22, 13q32-34, and 18q21-23; of these, 1q31-32, 11q23-25, 13q21-22, and 13q32-34 have previously not been described as amplified in NHL. This comprehensive cytogenetic characterization of 10 NHL cell lines identified novel sites of rearrangement and amplification; it also enhances their value in experimental studies aimed at gene discovery and gene function. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11807979     DOI: 10.1002/gcc.10025

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  The abnormalities of chromosome 8 in two hepatocellular carcinoma cell clones with the same genetic background and different metastatic potential.

Authors:  Jiong Yang; Lun-Xiu Qin; Sheng-Long Ye; Yin-Kun Liu; Yan Li; Dong-Mei Gao; Jie Chen; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-15       Impact factor: 4.553

2.  Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas.

Authors:  Weiyi Chen; Jane Houldsworth; Adam B Olshen; Gouri Nanjangud; Seeta Chaganti; Ennapadem S Venkatraman; Jeffrey Halaas; Julie Teruya-Feldstein; Andrew D Zelenetz; R S K Chaganti
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

3.  Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.

Authors:  Nancy Pennell; Anthony Woods; Marciano Reis; Rena Buckstein; David Spaner; Kevin Imrie; Karen Hewitt; Angela Boudreau; Arun Seth; Neil L Berinstein
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.

Authors:  Sarah C Rutherford; Angela A Fachel; Sheng Li; Seema Sawh; Ashlesha Muley; Jennifer Ishii; Ashish Saxena; Pilar M Dominguez; Eloisi Caldas Lopes; Xabier Agirre; Nyasha Chambwe; Fabian Correa; Yanwen Jiang; Kristy L Richards; Doron Betel; Rita Shaknovich
Journal:  Blood       Date:  2018-07-02       Impact factor: 22.113

5.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Authors:  Leandro C Cerchietti; Jose M Polo; Gustavo F Da Silva; Pedro Farinha; Rita Shaknovich; Randy D Gascoyne; Steven F Dowdy; Ari Melnick
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines.

Authors:  Wei Yu; Jun Inoue; Issei Imoto; Yoshinobu Matsuo; Abraham Karpas; Johji Inazawa
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

7.  Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Authors:  Cheng Li; Sang-Woo Kim; Deepak Rai; Aswani R Bolla; Siddharth Adhvaryu; Marsha C Kinney; Ryan S Robetorye; Ricardo C T Aguiar
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

8.  Tumorigenic activity and therapeutic inhibition of Rheb GTPase.

Authors:  Konstantinos J Mavrakis; Hong Zhu; Ricardo L A Silva; John R Mills; Julie Teruya-Feldstein; Scott W Lowe; Wayne Tam; Jerry Pelletier; Hans-Guido Wendel
Journal:  Genes Dev       Date:  2008-08-15       Impact factor: 11.361

9.  Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

Authors:  Sally E Trabucco; Rachel M Gerstein; Andrew M Evens; James E Bradner; Leonard D Shultz; Dale L Greiner; Hong Zhang
Journal:  Clin Cancer Res       Date:  2014-07-09       Impact factor: 12.531

10.  Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide.

Authors:  Jolanta Skalska; Paul S Brookes; Sergiy M Nadtochiy; Shannon P Hilchey; Craig T Jordan; Monica L Guzman; Sanjay B Maggirwar; Margaret M Briehl; Steven H Bernstein
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.